Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TLR3

TLR3

Brief Information

Name:Toll like receptor 3
Target Synonym:CD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TL3-M5255 Mouse Mouse TLR3 / CD283 Protein, Fc Tag (MALS verified)
TL3-M5255-structure
TL3-M5255-sds
TL3-H5253 Human Human TLR3 Protein, Fc Tag (MALS verified)
TL3-H5253-structure
TL3-H5253-sds

Part of Bioactivity data

TL3-M5255-MALS-HPLC
Human TLR3, Fc Tag (Cat. No. ) MALS images

The purity of Human TLR3, Fc Tag (Cat. No. TL3-M5255) is more than 90% and the molecular weight of this protein is around 235-287 kDa verified by SEC-MALS.

  • Background
    Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    TL3-H5253-MALS-HPLC
    Human TLR3, Fc Tag (Cat. No. ) MALS images

    The purity of Human TLR3, Fc Tag(Cat. No. TL3-H5253) is more than 90% and the molecular weight of this protein is around 265-285 kDa verified by SEC-MALS.

Synonym Name

TLR3,CD283,IIAE2

Background

Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rintatolimod Approved Hemispherx Biopharma Ampligen, Rintamod Argentina Fatigue Syndrome, Chronic Hemispherx Biopharma 2017-01-01 Pancreatic Neoplasms; Fatigue Syndrome, Chronic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PGV-001 PGV-001 Phase 1 Clinical Genentech Inc, Icahn School Of Medicine At Mount Sinai Neoplasms Details
CNTO-5 CNTO-5 Phase 1 Clinical Morphosys Ag Inflammation Details
Respiratory syncytial virus vaccine oral (Vaxart) VXA-RSV-f Vaxart Details
TR-987 Z-101; GLYC-101; MG-3601 Kazia Therapeutics Details
H5N1 avian influenza virus vaccine (Vaxart) ND-1; ND-1.1 Vaxart Details
Monovalent norovirus Vaccine (Vaxart) VXA-G1-1-NN; VXA-G1.1-NN Vaxart Details
Poly ICLC (Oncovir) Phase 2 Clinical Yamasa Corp, National Institutes Of Health Lymphoma, B-Cell; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Anemia, Refractory; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Smoldering Multiple Myeloma; Mesothelioma; Colorectal Neoplasms; Glioma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Melanoma; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message